Saarbrücken, Germany.
Introduction
17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) catalyses the NAD(P)H dependent transformation of estrone (E1) to 17β-estradiol (E2) which represents the most potent estrogen in humans ( fig. 1 ). [1] E2 is known to play a crucial role in the development and progression of several estrogen dependent diseases (EDD). [2] [3] [4] [5] Increased E2/E1 ratios as well as elevated 17β-HSD1 mRNA levels are indicators of the involvement of 17β-HSD1 in breast cancer [6, 7] , ovarian tumor [8] , endometriosis [9] , endometrial hyperplasia [10] and other EDD [11] . Consequently, the selective inhibition of this enzyme is considered as a valuable treatment option. This intracrine concept has recently been supported by the observation that an 17ß-HSD1 inhibitor tool compound can effectively block the increased E2 synthesis in endometriotic tissue specimens. [12] Due to the tissue-selective expression and the intracrine mode of action of 17β-HSD1 [13] , its inhibition should be associated with less side effects compared to established treatments using GnRH-analogs, aromatase inhibitors, anti-estrogens or selective estrogen receptor modulators (SERMs). [14] [15] [16] 17β-HSD2 catalyses the reverse reaction (inactivation of E2 to E1, fig. 1 ). Therefore, inhibitors of 17β-HSD1 should be selective over the type 2 enzyme.
Figure 1
Therapeutics interfering with intracrine pathways of hormone biosynthesis are already in clinical use, e.g. 5α-reductase inhibitors. [17] [18] [19] [20] Although a number of steroidal and nonsteroidal inhibitors of 17β-HSD1 [21] [22] [23] are described and there is experimental evidence for the effectiveness of 17β-HSD1 inhibition against human tumor cell lines in vitro and in animal models, there is no inhibitor under clinical evaluation. Moreover, no proof of principle study in an animal disease model has been conducted for the indication endometriosis, although this is a widespread disease for which no adequate medical treatment is available. A reason for this are interspecies differences between human 17β-HSD1 and animal orthologs which impede corresponding in vivo experiments, for instance in rodents. [24] Thus, human and mouse 17β-HSD1 are 83 % similar in the first 287 amino acids and show significant differences concerning the topology of the substrate binding site. [25, 26] As a consequence, compounds highly active towards the human enzyme are often weakly active or inactive towards rodent 17β-HSD1. The aim of this study was the design of compounds inhibiting both human and rodent 17β-HSD1. Such a compound may be used in a proof of principle study in an animal endometriosis model and may serve as potential candidate for clinical development afterwards. Starting point for the design was the class of bicyclic substituted hydroxyphenylmethanones (BSHs). [27] [28] [29] In contrast to most other classes of 17β-HSD1 inhibitors described by us [30] [31] [32] [33] [34] [35] [36] [37] [38] , it contains members which not only are strong inhibitors of the human enzyme but also show inhibition of the murine ortholog (previously unpublished results, fig.2 ). Examples are compounds D and E ( fig. 2 ). [27, 28] Drug design was focused on compound E as a lead and included structural variations with the aim of enhancing inhibitory activity towards rodent 17β-HSD1 while maintaining activity towards the human enzyme. 
Design
In a screening across all compound classes of our in-house compound library, the BSH E ( fig.  2 ) showed the highest inhibitory activity against murine 17β-HSD1 (for data of other compound classes cf. Supplementary Table S3 ). Compounds from the same class lacking the aromatic sulfonamide moiety displayed slightly inferior activity (compare compounds D and E, fig. 2 ). Thus, the aromatic sulfonamide moiety in combination with the BSH scaffold not only leads to a favourable activity profile against human 17β-HSD1 and 2 [28] , but it also appears to be attractive in terms of activity against murine 17β-HSD1.
The fact that E was the only BSH bearing an aromatic sulfonamide group prompted us to investigate this structural element in more detail (chart 1). Its optimal position on the phenyl ring C was determined (compounds 1-10), and analogous amides were investigated as possible bioisosteres (compounds 11 and 12). Moreover, compounds 13-29 with diverse substituents on ring D were prepared in a parallel synthesis approach in order to explore the chemical space more thoroughly.
Judging from previous data, fluorination of ring A could be beneficial. However, the introduction of a single fluorine atom was not expected to lead to a pronounced enhancement of activity. [27, [39] [40] [41] Therefore, a structural optimiziation was performed which focused on the introduction of two fluorine atoms into the benzoylic moiety (ring A; compounds 30-33), considering the following structure activity relationships obtained in previous studies: [27, 28]  the OH-group on the benzoylic moiety (ring A) is very important for activity  only minor structural variations in this part are tolerated by the human target enzyme Finally, ring D was replaced with heterocycles or cyclopropyl in order to decrease the lipophilicity of the fluorinated sulfonamide compounds (compounds 34-38).
Chart 1
An overview on the synthesised compounds 1-38 is given in the supporting information (Chart S1)
Chemistry
The key intermediates I and II were synthesised in good yields from the appropriate benzoyl chlorides and 2-bromothiophene using Friedel-Crafts conditions (scheme 1). Subsequent ether cleavage [42] (method A) yielded III and IV in quantitative yields, respectively.
III was reacted with 4-aminophenylboronic acid pinacol ester in a Suzuki cross coupling reaction [43] to afford the final compound 1. Compounds 2 and 30 were prepared from I and II, respectively, using the same methods as for 1 but in reversed order because the intermediates 2a and 30a were needed as starting materials in the syntheses according to scheme 2, vide infra.
The sulfonamides 3-28 and 34-36 were synthesised by reaction of 1, 2 and 30, respectively, with the corresponding sulfonic acid chlorides at room temperature. Cleavage of the ether function of 28 gave the dihydroxylated compound 29. (Scheme 1)
Scheme 1
Reaction of 2a with 3-methoxybenzenesulfonyl-or 3-methoxybenzoyl chloride yielded the corresponding intermediates 10a and 11a, which were submitted to ether cleavage to give the final compounds 10 and 11, respectively. (Scheme 2)
N-Methylation of compound 11a with methyl iodide afforded 12a which was reacted with BBr 3 in dichloromethane (method A) to give 12.
Interestingly, the synthesis of the fluorinated sulfonamides 31-33 starting from the phenol 30 (in analogy to the preparation of the fluorinated sulfonamides 34-36) proved to be difficult due to purification issues. This problem could be solved by employing the ether intermediate 30a instead of the phenol 30 as starting material and conducting O-demethylation of the intermediates 31a-33a as the final step.
Scheme 2
The synthesis of compounds 37 and 38 started with the reaction of 3-methyl-5-bromoaniline and cyclopropanesulfonyl chloride to afford 37b (Scheme 3). Subsequent methylation yielded the N-methyl sulfonamide 38b. Intermediates 37b and 38b were converted to the corresponding boronic acid esters 37a and 38a by a Pd-catalyzed reaction with bis(pinacolato)diboron in the presence of potassium acetate in DMSO. Suzuki cross coupling reaction with IV afforded the final compounds 37 and 38.
Scheme 3

Biological results
Inhibition of human and rodent 17β-HSD1and 2
Human placenta was used as source for h17β-HSD1, the enzyme was obtained according to described methods. [44] [45] [46] Recombinant mouse 17β-HSD1 and rat 17β-HSD1 were transiently expressed in HEK293 cells. Incubations were run with cytosolic fractions, tritiated E1, cofactor and inhibitor. The type 2 enzymes were obtained from the microsomal fractions of human placenta or mouse and rat liver, respectively. See experimental part for details. The separation of substrate and product was accomplished by HPLC (tables 1-3).
Inhibition of h17β-HSD1 by compounds 3-8 was strongly dependent on the position of the sulfonamide nitrogen at the phenyl ring C: compounds bearing the sulfonamide moiety in mposition to the thiophene ring (compounds 6-8, table 1) showed significantly higher inhibitory potency compared to their corresponding p-substituted isomers 3-5. Interestingly, the parent anilines 1 and 2 displayed a reversed correlation between position of the nitrogen atom and inhibitory potency. Bioisosteric replacement of the benzenesulfonic moiety of compound 6 with a thiophenesulfonic group led to compound 9 with similar activity. The m-sulfonamide function may be bioisosterically replaced by the amide function as can be seen by comparison of the inhibitory potencies of compounds 10 and the only slightly less active 11 (table 1) . Methylation of the amide group decreased activity (compound 12). Among compounds 1-12, inhibitor 7 showed the highest activity towards h17β-HSD1 (IC 50 = 8 nM) and the highest selectivity towards the human type 2 enzyme (SF = 25). Representative compounds bearing electron-donating or -withdrawing substituents were tested for inhibition of m17β-HSD1 but only showed weak activities of 26 % and below at 1 µM.
Table 1
The favourable h17β-HSD1 inhibition and selectivity data of compound 7 prompted us to investigate the effect of different substituents on the benzenesulfonyl moiety on inhibitory potency in more detail. Thus, compounds 13-29, bearing the sulfonamide moiety in the 3-position of the phenyl ring (ring C) were synthesised ( 50 = 80 and 97 nM, respectively). Moreover, the activity towards 17β-HSD2 was less pronounced in case of the rat compared to mouse. Table 3 5. Molecular modeling
Choice of Receptor Coordinates
A multitude of ligand-h17β-HSD1 complex structures have been solved to date and are available from the protein data bank. [47] As the choice of receptor coordinates as a starting point for in silico studies may significantly influence computed results, we carefully surveyed selected ternary structures with cofactor and additional ligand coordinates for their applicability in our experiments. Interestingly, some important structural differences can be observed when comparing for example the co-crystal of estradiol bound to h17β-HSD1 (PDB-ID: 1FDT) with that one of reported inhibitor E 2 B (PDB-ID 3HB5). [48, 49] In the former complex, the side chain of Lys195 is oriented inwards and towards the active site, thereby occupying a notable volume of the inhibitor binding region (see Supporting Figure S1 ). On the other hand, in 3HB5 this side chain is oriented outside of the protein. This is enabled by a quite significant change in backbone conformation. As a consequence, the otherwise partly occluded carboxamide group of Asn152 is easily accessible for attractive interactions with the inhibitor. In a previous study, we proposed that such interactions might be important for h17β-HSD1 inhibitors structurally related to the compounds reported herein.
[28] Hence, we reasoned that 3HB5 could be the ideal starting point for further in silico studies.
Docking to h17β-HSD1, Refinement and Analysis
Initial attempts to directly dock highly potent inhibitor 33 to h17β-HSD1 yielded ambiguous results only. We accounted this observation to the high degree of conformational freedom within this structure due to seven rotatable bonds. Hence, we followed a more user-guided approach towards binding pose prediction. Initially, structure preparation was performed. Then, pharmacophore features were defined which were based on the co-crystallised inhibitor E 2 B showing some structural similarity to our inhibitor scaffold (see Supplementary Figure  S1 ). A pharmacophore-guided docking was performed using compound 30 which has only a few rotatable bonds and, thus, displays the lowest degree of conformational freedom among the highly potent h17β-HSD1 inhibitors. The docking result was further refined by energy minimization. Finally, the additional bulky sulfonamide moiety of 33 was modelled into the ligand. The resulting predicted complex structure is given in Figure 3A and B. Due to the rather linear shape of the active site, the sulfonamide and the D ring are very likely to be oriented towards the exit of the binding pocket, providing the possibility to form a favourable hydrogen bond with His221.
As a control, we also docked E 2 B using the pharmacophore-guided procedure and the resulting binding pose showed an RMSD value of 0.3758 Å compared to the co-crystal structure (Supplementary Figure S2) . Finally, we also applied this docking protocol to compound 33. Again, ambiguous results were obtained. However, among the suggested binding poses very similar h17β-HSD1:33 complex structures were identified showing the same key interactions (see Supplementary Figure S2 ).
Our proposed binding model provides plausible explanations for the key SAR observations described above. The fluorination of the A ring had a noticeable beneficial effect on binding affinity to h17β-HSD1. This is nicely reflected by the strength of the hydrogen bond between Asn152 and the 3-hydroxy group computed for compound 33 ( Figure 3C ) and a non-fluorinated hypothetical derivative ( Figure 3D ). Additional calculations of pK a values for this hydroxyl group showed that the presence of fluorine substituents on ring A strongly influences the polarization of the O-H bond through modulation of electron density at the oxygen (Table S2 Supporting Information) . This leads to a more acidic character and renders the hydroxyl group a better hydrogen bond donor. Hence, we conclude that possible additional direct interactions between the fluorine atoms and the protein or an ortho-effect on ligand conformation are at least of minor importance for the beneficial outcome of fluorination.
Figure 3
Homology Modeling of m17β-HSD1
Finally, we generated a homology model for the homologous mouse enzyme in complex with inhibitor 33. To this end, we employed a built-in protocol of MOE which allows to employ ligand atoms as environment for side chain refinement. The respective m17β-HSD1:33 complex was generated using this method. Interestingly, the Asparagine residue which we propose to be involved in the described affinity-determining hydrogen bond is replaced by Histidine ( Figure 3E ). Although the imidazole side chain functionality can in principle exert the same interactions as the carboxamide group of Asn152, it is obvious that this exchange has a huge spatial and electronic impact on the predicted interaction. In line with these considerations, we find that the strength of the possible hydrogen bond between Histidine and inhibitor within the m17β-HSD1 complex is dramatically decreased in comparison to its (human) Asparagine congener.
Difference in activity towards mouse and rat 17β-HSD1
The observed general preference of the 17β-HSD1 inhibitors towards the rat over the mouse isoform might be caused by rather subtle changes within the protein structure, as these enzymes are very similar, sharing a sequence identity of 93 %. Comparing both sequences and taking our homology model of m17β-HSD1 into account, we identified four sites with amino acid exchanges that might have an influence on inhibitor binding: Tyr194His, Val198Glu, Leu220Gln, and Gln281Arg. Actually, these are the only residues in proximity to the ligand binding site which show a difference between mouse and rat. In the proposed binding mode no direct interactions between these residues and the ligand could be detected. However, Tyr194His is located in the helix/loop region which adopts different conformations within available X-ray structures for the human homolog (e.g. 1FDT vs 3HB5, vide supra 5.1 Choice of Receptor Coordinates). As this part of the protein is obviously quite flexible in case of h17β-HSD1, we speculate that both rodent enzymes may also adopt conformations where Tyr194 or His194 are facing towards the ligand binding site, facilitating direct interactions with the ligand or indirectly influencing side chain geometries of neighboring residues, affecting ligand affinity. Hence, we hypothesize that this amino acid exchange is the reason for the observed differences between m17β-HSD1 and r17β-HSD1 inhibition. The other mentioned residues (Val198Glu, Leu220Gln, and Gln281Arg) are located at more distant positions (see Supplementary Figure S5 ). However, an indirect effect on inhibitor binding through subtle influence on the backbone or the side chains which are in contact with the ligands cannot be excluded.
Discussion and Conclusions
The aim of the present study was the search for potent inhibitors of both human and rodent 17β-HSD1, which can pave the way to a proof of principle study in an animal disease model for EDD. The class of sulfonamide-substituted BSHs was chosen as a starting point because this compound class, in contrast to others, is characterized not only by high inhibitory potency towards human 17β-HSD1, but also by activity towards the murine enzyme.
Modifying the substitution pattern on the sulfonamide moiety did not result in compounds with the desired inhibitory profile. The introduction of fluorine atoms on the benzoyl moiety, however, led to the discovery of highly active inhibitors of h17β-HSD1. In addition, strong inhibition of the rodent enzymes, especially rat 17β-HSD1, was observed for some compounds. Computational analyses suggested that the increase of inhibitory activity was due to a beneficial influence of fluorination on the hydrogen bonding properties of the adjacent OH-group. Lower potencies towards rodent compared to human 17β-HSD1 are in agreement with differences in the architectures of the ligand binding sites and nearby regions, as comparisons between a crystal structure of h17β-HSD1 and homology models of the corresponding murine and rat enzymes indicated.
Compound 33 is one of the most active inhibitors of human 17β-HSD1 ever described. Moreover, it displayed strong inhibition of the rat ortholog. Its inhibition of the type 2 enzyme is less pronounced for the rat than for the mouse. Thus, compound 33 is a lead for further optimisations in order to obtain a suitable candidate which can be used in a proof of principle study in a rat endometriosis model. The minimally required 17ß-HSD1 selectivity over 17ß-HSD2 is not known at the present time. In endometriotic tissue of patients with endometriosis, due the increased activity of 17ß-HSD1, higher than expected concentrations of inhibitor may be required for normalization of E2 synthesis. In healthy endometrial tissue, the intracellular E2 concentrations during the proliferative phase are 5-8 fold higher than in the serum [50] . In endometriotic tissue samples of patients with endometriosis, the intracellular E2 concentrations remain higher over E1 throughout the whole menstrual cycle. In the rat endometriosis model, endometrial explants, that are autologously transplanted to ectopic sites outside the uterus, also contain very high levels of E2, about two orders of magnitude higher than in the serum [51] . Yet, at the same time, because of significantly increased intracellular concentration of E2 in endometriotic tissue [50, 51] , it may also be difficult for the compound to compete with E2, and thus a higher than expected selectivity towards 17ß-HSD1 inhibition is also possible. Recently, a more than 100-fold selective (and estrone-derived) 17ß-HSD1 inhibitor has been shown to effectively block the increased E2 synthesis in human endometriotic tissue specimens [12] . A 100-300-fold selectivity may thus be sufficient for a proof of principle study in a rat endometriosis model.
Experimental Section
7.1 Chemical Methods. Chemical names follow IUPAC nomenclature. Starting materials were purchased from Aldrich, Acros, Lancaster, Maybridge, Combi Blocks, Merk, or Fluka and were used without purification.
Column chromatography (CC) was performed on silica gel (70 -200µm), reaction progress was monitored by thin layer chromatography (TLC) on Alugram SIL G UV 254 (Macherey-Nagel). Mass spectra (ESI) were recorded on a TSQ Quantum (Thermo Finnigan) instrument.
Tested compounds are >95% chemical purity as measured by HPLC. The methods for HPLC analysis and a table of data for all tested compounds are provided in the supplementary data section.
The following compounds were prepared according to previously described procedures: The Supplementary Data section reports the synthesis of compounds 4-28, 10a, 11a, 30a, 29-38 and 37b. For each general synthetic procedure, one representative example is given below
(5-Bromothiophene-2-yl)-(3-ethoxy-2,6-difluorophenyl)methanone (II).
An ice-cooled mixture of 2-bromothiophene (2.217 g, 13.60 mmol), 2,6-difluoro-4-ethoxybenzoyl chloride (3.000 g, 13.60 mmol) and aluminum chloride (1.813 g, 13.60 mmol) in anhydrous dichloromethane (25 mL) was warmed to room temperature and stirred for 2-4 h. 1M HCl (50 mL) was used to quench the reaction. The aqueous layer was extracted with dichloromethane (3 x 50 mL). The combined organic layers were washed with brine (50 mL), dried over magnesium sulfate, filtered, and concentrated to dryness. The product was purified by CC (hexane/ethyl acetate 97:3); yield: 79% (3740 mg). 1 
General procedure for ether cleavage. Method A (IV, 10-12, 29-33)
To a solution of methoxybenzene derivative (8 mmol, 1 equiv) in anhydrous dichloromethane (20 mL) at -78 o C (dry ice/acetone bath), boron tribromide in dichloromethane (1M, 3 equiv per methoxy function) was added dropwise. The reaction mixture was stirred overnight at room temperature under nitrogen atmosphere. Water (50 mL) was added to quench the reaction, and the aqueous layer was extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine (50 mL), dried over magnesium sulfate, filtered, and concentrated to dryness. The product was purified by CC.
(5-Bromothiophene-2-yl)-(2,6-difluoro-3-hydroxyphenyl)methanone (IV).
The title compound was prepared by reaction of (5-bromothiophene-2-yl)-(3-ethoxy-2,6-difluorophenyl)methanone (V) (3.00 g, 8.64 mmol) and boron tribromide (43.2 mmol, 5 equiv) according to Method A. The product was purified by CC (hexane/ethyl acetate 9:1); yield: 84% (2.310 g). MS (ESI): 320.12 (M+H) + .
General procedure for Suzuki coupling. Method B (1, 30a, 37, 38)
A mixture of arylbromide (0.50 mmol, 1 equiv), boronic acid derivative (1.2 equiv), cesium carbonate (4 equiv) and tetrakis(triphenylphosphine) palladium (0.01 equiv) was suspended in an oxygen-free DME/water (1:1, 25 mL) solution and refluxed under nitrogen atmosphere. The reaction mixture was cooled to room temperature. The aqueous layer was extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine (50 mL), dried over magnesium sulfate, filtered and concentrated to dryness. The product was purified by CC.
(5-(4-Aminophenyl)thiophene-2-yl)(3-hydroxyphenyl)methanone (1)
The title compound was prepared by reaction of (5-bromothiophene-2-yl)(3-hydroxyphenyl)methanone (III) (140 mg, 0.50 mmol), 4-aminophenylboronic acid pinacol ester (155 mg, 0.71 mmol), cesium carbonate (658 mg, 2.02 mmol) and tetrakis(triphenylphosphine) palladium (6.00 mg, 5.00 µmol) according to Method B. The product was purified by CC (dichloromethan/methanol 99:1); yield: 82% (120 mg). 1 C (3-9, 10a, 11a, 13-28,  34-36, 37b) The amino phenyl derivative (0.4 mmol, 1 equiv) was dissolved in pyridine absolute (3 mL) and was spiked with sulfonyl chloride/acid chloride (1.5 equiv). The reaction mixture was stirred overnight at rt (refluxed in case of amide coupling). The reaction was quenched by adding 10 mL of 2N HCl and extracted with ethyl acetate (3 x 50 mL). The organic layers were washed with saturated NaHCO 3 (50 mL) and brine (50 mL), dried over magnesium sulfate, filtered and concentrated to dryness. The product was purified by CC.
N-(4-(5-(3-Hydroxybenzoyl)thiophene-2-yl)phenyl)benzenesulfonamide (3)
The title compound was prepared by reaction of (5-(4-aminophenyl)thiophene-2-yl)(3-hydroxyphenyl)methanone (1) (100 mg, 0.34 mmol) and benzenesulfonyl chloride (90 mg, 0.51 mmol) according to Method C. The product was purified by CC (dichloromethan/methanol 99.5:0.5); yield: 77% (114 mg). 1 (R t = 11.57 min).
3-Methoxy-N-(3-(5-(3-methoxybenzoyl)thiophene-2-yl)phenyl)-N-methylbenzamide (12a)
A mixture of 3-methoxy-N-(3-(5-(3-methoxybenzoyl)-thiophene-2-yl)phenyl)benzamide (11a) (666 mg, 1.50 mmol, 1 equiv) and NaH (60% suspension in mineral oil, 3.00 mmol, 2 equiv) in DMF (20 mL) was stirred for 30 min at room temperature, then iodomethane (213 mg, 1.50 mmol, 2 equiv) was added. After 30 min the reaction mixture was poured into water (50 mL). The resulting precipitate was collected, washed with water (50 mL), dried, and purified by CC (hexane/ethyl acetate 3:2); yield: 42% (290 mg). 1 
Cyclopropanesulfonic acid (3-methyl-5-(4,4,5,5-tetramethyl-(1,3,2)dioxaborolan-2-yl)-phenyl)-amide (37a) and cyclopropanesulfonic acid methyl-(3-methyl-5-(4,4,5,5-tetramethyl-(1,3,2)dioxaborolan-2-yl)-phenyl)-amide (38a)
Cyclopropanesulfonic acid (3-bromo-5-methylphenyl)-amide (37b) (800 mg, 2.76 mmol, 1 equiv) or cyclopropanesulfonic acid (3-bromo-5-methylphenyl)methyl-amide (38b) (260 mg, 0.86 mmol, 1equiv) was dissolved in 10 mL of dry dimethyl sulfoxide (3 mL for compound 38b) under N 2 atmosphere to prepare the title compounds 37a and 38a, respectively. Bis(pinacolato)diborone (1.5 equiv), potassium acetate (3 equiv) and Pd(dppf)Cl 2 (0.05 equiv) were added. The reaction mixture was heated to 80°C over night. The reaction mixture was cooled down to room temperature, quenched with water (50 mL) and diethyl ether (50 mL), filtered over celite and extracted three times with diethyl ether (3 x 50 mL). The ethereal solutions were washed three times with water (50 mL) and brine (50 mL), dried over magnesium sulphate, filtered and evaporated under reduced pressure. Purification was accomplished by CC (dichloromethane pure to dichloromethane/methanol 8:2); yield: 16% (150 mg, compound 37a) and 50% (150 mg, compound 38a). The product was used in the next step without characterization.
Cyclopropanesulfonic acid (3-bromo-5-methyl-phenyl)-methyl-amide (38b)
Cyclopropanesulfonic acid (3-bromo-5-methylphenyl)amide (37b) (100mg, 0.345mmol, 1equiv) was dissolved in 1 mL anhydrous dimethyl formamide and cooled to 0°C under N 2 atmosphere. Sodium hydride (10.0 mg, 0.414 mmol, 1.2 equiv) was added and the solution was stirred for 10 min. Methyl iodide (54 mg, 0.024 mL, 0.38 mmol, 1.1equiv) was added slowly. The mixture was stirred at room temperature over night. The mixture was quenched with water (50 mL) and extracted three times with diethyl ether (3 x 50 mL). The ethereal solutions were combined, washed 5 times with water (50 mL) and brine (50 mL) and dried over sodium sulphate. The solvent was evaporated under reduced pressure. No further purification was required; yield: 81% (85 mg). 1 
Preparation of human 17β-HSD1 and 17β-HSD2.
Human 17β-HSD1 and 17β-HSD2 were obtained from human placenta according to previously described procedures. [44] Fresh human placenta was homogenized, and cytosolic fraction and microsomes were separated by fractional centrifugation. For the partial purification of 17β-HSD1, the cytosolic fraction was precipitated with ammonium sulfate. 17β-HSD2 was obtained from the microsomal fraction.
Inhibition of human 17β-HSD1.
Inhibitory activities were evaluated by an established method with minor modifications. [44] Briefly, the enzyme preparation was incubated with NADPH (500 µM) in the presence of potential inhibitors at 37 o C in a phosphate buffer (50 mM) supplemented with 20% of glycerol and EDTA (1 mM). Inhibitor stock solutions were prepared in DMSO. The final concentration of DMSO was adjusted to 1% in all samples. The enzymatic reaction was started by addition of a mixture of unlabelled-and [2,4,6,7- 3 H]-E1 (final concentration: 500 nM, 0.15 µCi). After 10 min, the incubation was stopped with HgCl 2 and the mixture was extracted with diethylether. After evaporation, the steroids were dissolved in acetonitrile. E1 and E2 were separated using acetonitrile/water (45:55) as mobile phase in a C18 reverse phase chromatography column (Nucleodur C18 125/3 100-5, Macherey-Nagel) connected to a HPLC-system (Agilent 1200 Series, Agilent Technologies). Detection and quantification of the steroids were performed using a radioflow detector (Ramona, raytest). The conversion rate was calculated after analysis of the resulting chromatograms according to the following equation:
Each value was calculated from at least three independent experiments.
Inhibition of human 17β-HSD2.
The h17β-HSD2 inhibition assay was performed similarly to the h17β-HSD1 procedure. 
Preparation of mouse and rat 17β-HSD1 and 2.
Recombinant mouse and rat 17β-HSD1 enzymes were produced by transfection of HEK293 cells with a mouse or rat 17β-HSD1 expression plasmid purchased from OriGene Technologies, Inc. (Rockville, USA). 48 hours after transfection, cells were homogenised by ultrasonication (3x10s) in a buffer containing sucrose (40 mM Tris, 250 mM sucrose, 5 mM EDTA, 7 mM DTT, 1 mM PMSF, pH 7.5). Cell lysates were centrifuged (1,000g, 15 min, 4°C) and 20% glycerol was added to the supernatant before aliquots were frozen and stored at -70°C. Microsomal 17β-HSD2 fractions were obtained from mouse or rat liver. Fresh liver tissues were processed as described for the human placental 17β-HSD2 preparation. The pellet fractions containing the microsomal 17β-HSD2 were used for the determination of E1 formation.
Inhibition of mouse and rat 17β-HSD1.
Inhibitory activities of the compounds towards mouse or rat 17β-HSD1 were evaluated by a method similar to the human 17β-HSD1 assay. The recombinant enzyme preparations were incubated with NADPH (500 µM), test compound and a mixture of unlabeled-and [2, 4, 6, The protein structure 3HB5 was prepared for docking by applying the LigX protocol of MOE (Chemical Computing Group) using the default parameters. Hence, structure preparation and protonate 3D (allowing side chain flips) algorithms were applied and receptor atoms were tethered with a strength of 10 and a buffer of 0.25. Additionally, all atoms farther than 8 Å from the ligand were automatically fixed and the refinement step used a gradient of 0.1 kcal/mol/Å.
After structure preparation, a constrained four-feature pharmacophore model was set up to guide the initial ligand placement in the docking procedure (see Supplementary Figure S1 , Supporting Information). The native ligand was used to define the binding site. Then, compounds 30, E2B, and compound 33 (see Supplementary Figure S2 ) were docked to the prepared protein-cofactor complex using the "induced fit" protocol with default parameters and the described pharmacophore features being active. The placement algorithm was "Triangle Matcher" with 30 retained poses and "London dG" as rescoring function. The refinement step was carried out using the "Forcefield" option and "GBVI/WSA dG" as the second rescoring function with 30 retained poses.
The ten highest scoring binding poses of compound 30 were evaluated and the most abundant ligand orientation (8/10) was further refined by optimizing hydrogen bond geometry followed by an additional energy minimization step. Then, the 2-trifluoromethylbenzenesulfonamide moiety of 33 was modelled into the generated binding pose of compound 30 by adding the respective atoms starting with the sulfonamide moiety expanding the molecule with minimal clashes. Finally, energy minimization yielded proposed binding pose of compound 33 (see also Supplementary Figure S2) . All steps were performed with MOE using the AMBER10:EHT force field and the R-Field solvation model
Homology modelling
The models of the mouse and rat enzymes (m17β-HSD1 and r17β-HSD1) were generated using the built-in "homology model" function of MOE. We used the structure of our ternary h17β-HSD1:33:cofactor complex (see above) as template coordinates. The sequences of the mouse and rat isoforms were obtained from NCBI via accession codes NP_034605.1 (mouse) and NP_036983.1 (rat). First, the sequence of respective isoform was loaded into MOE and the sequence was aligned to the human isoform (see also Supplementary Figure S3) . Then, ligand atoms (compound 33 and cofactor NADP) were selected as environmental constrain for induced fit optimisation. The default parameters were used (10 models with 1 side chain sample at 300K). The resulting 10 models were scored by the built-in GB/VI (default) algorithm. The highest scoring model was automatically refined with an RMS gradient of 0.5 (default). The yielded ligand binding poses for compound 33 bound to m17β-HSD1 and r17β-HSD1 were optimised using the LigX protocol with default parameters. All steps were performed using the AMBER10:EHT force field and the R-Field solvation model.
For evaluating model geometry we created Phi-Psi plots of the template coordinates (PDB-ID: 3HB5) and the homology models (see Supplementary Figure S4 ). In all three models only three out of 284 residues lay outside of the theoretically favoured regions indicating a good overall geometry. 4 , DME/water (1:1), reflux, 4h. d) Method C, pyridine, corresponding sulfonyl chloride, rt, overnight. 
